ICOS/B7 RP - 1在器官移植中的研究进展

ICOS 是作为 CD28 超家族中的新成员,ICOS 对 T 细胞的活化、分化都有独特的作用.以调控共刺激通路ICOS/B7RP - 1 通路为靶点,发挥 ICOS 与其他 CD28 家族成员间的相互作用、促使器官移植后免疫耐受的建立,必将成为以后器官移植的热点和重点.本文就就其在器官移植中的最新研究进展作一综述.     

ICOS/B7 RP - 1在器官移植中的研究进展

ICOS 是作为 CD28 超家族中的新成员,ICOS 对 T 细胞的活化、分化都有独特的作用.以调控共刺激通路ICOS/B7RP - 1 通路为靶点,发挥 ICOS 与其他 CD28 家族成员间的相互作用、促使器官移植后免疫耐受的建立,必将成为以后器官移植的热点和重点.本文就就其在器官移植中的最新研究进展作一综述.     

ICOS/B7 RP - 1在器官移植中的研究进展

ICOS 是作为 CD28 超家族中的新成员,ICOS 对 T 细胞的活化、分化都有独特的作用.以调控共刺激通路ICOS/B7RP - 1 通路为靶点,发挥 ICOS 与其他 CD28 家族成员间的相互作用、促使器官移植后免疫耐受的建立,必将成为以后器官移植的热点和重点.本文就就其在器官移植中的最新研究进展作一综述.     

ICOS/B7 RP - 1在器官移植中的研究进展

ICOS 是作为 CD28 超家族中的新成员,ICOS 对 T 细胞的活化、分化都有独特的作用.以调控共刺激通路ICOS/B7RP - 1 通路为靶点,发挥 ICOS 与其他 CD28 家族成员间的相互作用、促使器官移植后免疫耐受的建立,必将成为以后器官移植的热点和重点.本文就就其在器官移植中的最新研究进展作一综述.     

ICOS/B7 RP - 1在器官移植中的研究进展

ICOS 是作为 CD28 超家族中的新成员,ICOS 对 T 细胞的活化、分化都有独特的作用.以调控共刺激通路ICOS/B7RP - 1 通路为靶点,发挥 ICOS 与其他 CD28 家族成员间的相互作用、促使器官移植后免疫耐受的建立,必将成为以后器官移植的热点和重点.本文就就其在器官移植中的最新研究进展作一综述.     

ICOS/B7 RP - 1在器官移植中的研究进展

ICOS 是作为 CD28 超家族中的新成员,ICOS 对 T 细胞的活化、分化都有独特的作用.以调控共刺激通路ICOS/B7RP - 1 通路为靶点,发挥 ICOS 与其他 CD28 家族成员间的相互作用、促使器官移植后免疫耐受的建立,必将成为以后器官移植的热点和重点.本文就就其在器官移植中的最新研究进展作一综述.     

ICOS/B7 RP - 1在器官移植中的研究进展

ICOS 是作为 CD28 超家族中的新成员,ICOS 对 T 细胞的活化、分化都有独特的作用.以调控共刺激通路ICOS/B7RP - 1 通路为靶点,发挥 ICOS 与其他 CD28 家族成员间的相互作用、促使器官移植后免疫耐受的建立,必将成为以后器官移植的热点和重点.本文就就其在器官移植中的最新研究进展作一综述.     

ICOS/B7 RP - 1在器官移植中的研究进展

ICOS 是作为 CD28 超家族中的新成员,ICOS 对 T 细胞的活化、分化都有独特的作用.以调控共刺激通路ICOS/B7RP - 1 通路为靶点,发挥 ICOS 与其他 CD28 家族成员间的相互作用、促使器官移植后免疫耐受的建立,必将成为以后器官移植的热点和重点.本文就就其在器官移植中的最新研究进展作一综述.     

ICOS/B7 RP - 1在器官移植中的研究进展

ICOS 是作为 CD28 超家族中的新成员,ICOS 对 T 细胞的活化、分化都有独特的作用.以调控共刺激通路ICOS/B7RP - 1 通路为靶点,发挥 ICOS 与其他 CD28 家族成员间的相互作用、促使器官移植后免疫耐受的建立,必将成为以后器官移植的热点和重点.本文就就其在器官移植中的最新研究进展作一综述.     

ICOS/B7 RP - 1在器官移植中的研究进展

ICOS 是作为 CD28 超家族中的新成员,ICOS 对 T 细胞的活化、分化都有独特的作用.以调控共刺激通路ICOS/B7RP - 1 通路为靶点,发挥 ICOS 与其他 CD28 家族成员间的相互作用、促使器官移植后免疫耐受的建立,必将成为以后器官移植的热点和重点.本文就就其在器官移植中的最新研究进展作一综述.     

The Prognostic Value of E-Cadherin, α-, β-, and γ-Catenin in Urothelial Cancer of the Upper Urinary Tract

Objectives

To determine the value of loss of the expression of E-cadherin and cadherin-associated molecules as useful markers for both prognosis and bladder recurrence in patients with upper urinary tract cancer.

Materials and methods

In 61 paraffin-embedded nephroureterectomy specimens, the expression of E-cadherin and α-, β-, and γ-catenin was examined by immunohistochemical staining. To evaluate the prognostic significance, Kaplan-Meier survival curves were calculated and compared by the log-rank test. A multivariate test was performed to detect prognostic markers.

Results

Normal expression was found in 32 cases (52.5%) for E-cadherin, 41 cases (67.2%) for α-catenin, 42 cases (68.9%) for β-catenin, and 31 cases (50.8%) for γ-catenin. The expression patterns of E-cadherin and α-, β- and γ-catenin were significantly correlated with each other. Survival analysis showed a significant difference between normal and aberrant expression in each staining. Multivariate analysis revealed that tumor stage and the expression of E-cadherin were independent prognostic factors for cause-specific survival. In contrast, there was no significant correlation between the expression of E-cadherin and α-, β-, and γ-catenin and bladder recurrence.

Conclusion

Our data suggest E-cadherin may be a good prognostic marker for patients with upper urinary tract cancer.     

Is There a Role for Tamsulosin in the Treatment of Distal Ureteral Stones of 7 mm or Less? Results of a Randomised,Double-Blind,Placebo-Controlled Trial

Background

Numerous randomised trials have confirmed the efficacy of medical expulsive therapy with tamsulosin in patients with distal ureteral stones; however, to date, no randomised, double-blind, placebo-controlled trials have been performed.

Objective

The objective of this trial was to evaluate the efficacy of medical expulsive therapy with tamsulosin in a randomised, double-blind, placebo-controlled setting.

Design, setting, and participants

Patients presenting with single distal ureteral stones ≤7 mm were included in this trial.

Intervention

Patients were randomised in a double-blind fashion to receive either tamsulosin or placebo for 21 d. The medication was discontinued after either stone expulsion or intervention. Abdominal computed tomography was performed to assess the initial and final stone status.

Measurements and limitations

The primary end point was the stone expulsion rate. Secondary end points were time to stone passage, the amount of analgesic required, the maximum daily pain score, safety of the therapy, and the intervention rate.

Results

Ten of 100 randomised patients were excluded from the analysis. No statistically significant differences in patient characteristics and stone size (median: 4.1 mm [tamsulosin arm] vs 3.8 mm [placebo arm], p = 0.3) were found between the two treatment arms. The stone expulsion rate was not significantly different between the tamsulosin arm (86.7%) and the placebo arm (88.9%; p = 1.0). Median time to stone passage was 7 d in the tamsulosin arm and 10 d in the placebo arm (log-rank test, p = 0.36). Patients in the tamsulosin arm required significantly fewer analgesics than patients in the placebo arm (median: 3 vs 7, p = 0.011). A caveat is that the exact time of stone passage was missing for 29 patients.

Conclusions

Tamsulosin treatment does not improve the stone expulsion rate in patients with distal ureteral stones ≤7 mm. Nevertheless, patients may benefit from a supportive analgesic effect.

Clinicaltrials.gov

NCT00831701.     

组织因子/活性凝血7因子体外激活大肠癌LOVO细胞基质金属蛋白酶-7基因启动子

目的 观察组织因子(TF)/活性凝血7因子(FVIIa)复合物对大肠癌LOVO细胞系基质金属蛋白酶-7(MMP-7)基因启动子的激活.方法 靶向组织因子基因的小干扰RNA(siRNA)构建及稳定转染获得TFRNAi LOVO细胞系;Western blot检测组织因子的干扰效率;MMP-7基因上游5'非翻译区DNA调节序列及缺失体克隆到pGL3-basic荧光素酶报告基因载体;双报告基因检测FVIIa因子存在时,MMP7.lue1592、MMP7.luc 978、MMP7.luc 615瞬时转染LOVO细胞或TFR-NAi LOVO细胞启动子活性.结果 Western blot灰度半定量显示TFRNAi LOVO细胞中组织因子蛋白表达水平较LOVO细胞下降41.7%;双报告基因检测FVIIa因子存在时MMP7.luc1592具有启动子活性并依赖组织因子,活性区域位于MMP-7基因转录起始点上游-978 bp及-615 bp之间.结论 TF/FVIIa能直接激活大肠癌LOVO细胞系MMP-7基因启动子.